@article{TLCR118211,
author = {Hisashi Tanaka and Tomonori Makiguchi and Takehiro Tozuka and Yosuke Kawashima and Tomohiro Oba and Ryosuke Tsugitomi and Junji Koyama and Yuichi Tambo and Shinsuke Ogusu and Masafumi Saiki and Hiroshi Gyotoku and Tsukasa Hasegawa and Eisaku Miyauchi and Tomoaki Sonoda and Ryota Saito and Katsumi Nakatomi and Toshio Sakatani and Keita Kudo and Yuko Tsuchiya-Kawano and Makoto Nishio},
title = {Efficacy of ipilimumab plus nivolumab with or without chemotherapy according to baseline tumor size: a multicenter retrospective study},
journal = {Translational Lung Cancer Research},
volume = {15},
number = {6},
year = {2026},
keywords = {},
abstract = {Background: Ipilimumab plus nivolumab (I-N) with or without chemotherapy is an established first-line treatment for advanced non-small cell lung cancer (NSCLC). For patients with a large baseline tumor size (BTS), chemotherapy combined with immune checkpoint inhibitors (ICIs) has shown better outcomes compared with ICI monotherapy. However, the specific radiographic size criteria for determining whether to prioritize the CheckMate227 or CheckMate9LA regimen are undefined. Therefore, we evaluated how BTS impacts the efficacy of I-N-based therapy in our cohort.Methods: This multicenter retrospective study was conducted across 19 institutions in Japan. Adult patients with advanced NSCLC with programmed death-ligand 1 (PD-L1) tumor proportion score (TPS) 1–49% who received I-N-based therapy as first-line systemic treatment between January 2018 and March 2022 were included. We excluded patients with EGFR or ALK mutation. Patients were classified into two groups: the I-N group and the I-N-chemo group. Survival outcomes were evaluated based on BTS (≥50 vs. },
issn = {2226-4477}, url = {https://tlcr.amegroups.org/article/view/118211}
}